Immudex USA, LLC
Immudex manufactures Class I and Class II MHC Dextramers for the detection of CD8+ and CD4+ antigen-specific T cells. Under an agreement with the US Cancer Immunotherapy Consortium (CIC) and the European Cancer Immunotherapy Consortium (CIMT), Immudex also provides MHC Multimer and Elispot proficiency panel services worldwide. The 510(k) and CE-marked Dextramer CMV Kit is cleared for the quantification of CMV-specific T cells post allogenic stem cell transplant. Details at www.immudex.com.